ArticleHuman vaccines & immunotherapeutics2025
The construction of a prognostic nomogram model for colorectal cancer and the prediction of immune characteristics and immune treatment responses based on the bioinformatics analysis of soluble mediator-related genes.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate prognosis prediction in colorectal cancer (CRC) is essential for personalized treatment. Soluble mediators are promising predictive biomarkers for evaluating outcomes. We sourced transcriptome data of CRC (COAD+READ) from TCGA and GEO. Soluble mediator-related genes (SMRGs) were identified via GeneCards. Through univariate Cox and Lasso regression analyses, prognosis-related feature genes were determined. A prognostic model was created using multivariate Cox regression, categorizing patients into high-risk (HR) and low-risk (LR) groups based on the median riskscore. KEGG pathway enrichment analysis and GSEA were undertaken on groups. ssGSEA assessed immune cell scores, while ESTIMATE analysis evaluated stromal and immune cell scores along with tumor purity. The CellMiner database identified potential drugs for HR patients. Pearson correlation analysis revealed the relationship between mismatch repair (MMR) genes and model genes. We identified 10 SMRGs. Pearson correlation analysis indicated positive correlations among these genes. GO analysis showed that most feature genes were linked to binding functions. KEGG analysis revealed that the HR group was enriched in pathways like Basal cell carcinoma and Glycosaminoglycan biosynthesis. The ssGSEA indicated higher immune cell scores in the LR group, alongside lower stromal scores. LR group also exhibited a lower TIDE score and higher immunophenoscore. Drug sensitivity analysis suggested PF-4708671, PI-103, and XAV939 as potential treatments for HR patients. There was significant correlation between model gene and MMR genes. The CRC prognostic model based on SMRGs effectively predicts patient prognosis and guides treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.